Canaan X L.p. - Net Worth and Insider Trading

Canaan X L.p. Net Worth

The estimated net worth of Canaan X L.p. is at least $158 Million dollars as of 2024-04-25. Canaan X L.p. is the 10% Owner of IDEAYA Biosciences Inc and owns about 2,660,713 shares of IDEAYA Biosciences Inc (IDYA) stock worth over $102 Million. Canaan X L.p. is the 10% Owner of Protagonist Therapeutics Inc and owns about 2,116,552 shares of Protagonist Therapeutics Inc (PTGX) stock worth over $53 Million. Canaan X L.p. is also the 10% Owner of NextCure Inc and owns about 2,254,442 shares of NextCure Inc (NXTC) stock worth over $3 Million. Besides these, Canaan X L.p. also holds Iterum Therapeutics PLC (ITRM) . Details can be seen in Canaan X L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Canaan X L.p. has not made any transactions after 2019-05-28 and currently still holds the listed stock(s).

Transaction Summary of Canaan X L.p.

To

Canaan X L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Canaan X L.p. owns 5 companies in total, including Iterum Therapeutics PLC (ITRM) , IDEAYA Biosciences Inc (IDYA) , and NextCure Inc (NXTC) among others .

Click here to see the complete history of Canaan X L.p.’s form 4 insider trades.

Insider Ownership Summary of Canaan X L.p.

Ticker Comapny Transaction Date Type of Owner
ITRM Iterum Therapeutics PLC 2020-01-21 director & 10 percent owner
IDYA IDEAYA Biosciences Inc 2019-05-28 10 percent owner
NXTC NextCure Inc 2019-05-13 10 percent owner
PTGX Protagonist Therapeutics Inc 2018-05-17 10 percent owner
ASTR Astra Space Inc 2021-06-30 10 percent owner

Canaan X L.p. Latest Holdings Summary

Canaan X L.p. currently owns a total of 4 stocks. Among these stocks, Canaan X L.p. owns 2,660,713 shares of IDEAYA Biosciences Inc (IDYA) as of May 28, 2019, with a value of $102 Million and a weighting of 64.65%. Canaan X L.p. owns 2,116,552 shares of Protagonist Therapeutics Inc (PTGX) as of May 17, 2018, with a value of $53 Million and a weighting of 33.3%. Canaan X L.p. also owns 2,254,442 shares of NextCure Inc (NXTC) as of May 13, 2019, with a value of $3 Million and a weighting of 1.94%. The other 1 stocks Iterum Therapeutics PLC (ITRM) have a combined weighting of 0.11% among all his current holdings.

Latest Holdings of Canaan X L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
IDYA IDEAYA Biosciences Inc 2019-05-28 2,660,713 38.44 102,277,808
PTGX Protagonist Therapeutics Inc 2018-05-17 2,116,552 24.89 52,680,979
NXTC NextCure Inc 2019-05-13 2,254,442 1.36 3,066,041
ITRM Iterum Therapeutics PLC 2018-05-30 115,545 1.54 177,939

Holding Weightings of Canaan X L.p.


Canaan X L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Canaan X L.p. has made a total of 1 transactions in IDEAYA Biosciences Inc (IDYA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in IDEAYA Biosciences Inc is the acquisition of 400,000 shares on May 28, 2019, which cost Canaan X L.p. around $4 Million.

According to the SEC Form 4 filings, Canaan X L.p. has made a total of 0 transactions in Protagonist Therapeutics Inc (PTGX) over the past 5 years. The most-recent trade in Protagonist Therapeutics Inc is the sale of 38,968 shares on May 17, 2018, which brought Canaan X L.p. around $237,315.

According to the SEC Form 4 filings, Canaan X L.p. has made a total of 1 transactions in NextCure Inc (NXTC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in NextCure Inc is the acquisition of 50,000 shares on May 13, 2019, which cost Canaan X L.p. around $750,000.

More details on Canaan X L.p.'s insider transactions can be found in the Insider Trading History of Canaan X L.p. table.

Insider Trading History of Canaan X L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Canaan X L.p. Trading Performance

GuruFocus tracks the stock performance after each of Canaan X L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Canaan X L.p. is 20.83%. GuruFocus also compares Canaan X L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Canaan X L.p. within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Canaan X L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Canaan X L.p.

Average Return

4.11%

Average return per transaction

Outperforming Transactions

50%

2 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -4.86 20.83 10.84 4.11 -13.75 -24.87
Relative Return to S&P 500(%) -6.31 17.44 2.93 -1.91 -29.57 -37.92

Canaan X L.p. Ownership Network

Ownership Network List of Canaan X L.p.

No Data

Ownership Network Relation of Canaan X L.p.


Canaan X L.p. Owned Company Details

What does Iterum Therapeutics PLC do?

Who are the key executives at Iterum Therapeutics PLC?

Canaan X L.p. is the director & 10 percent owner of Iterum Therapeutics PLC. Other key executives at Iterum Therapeutics PLC include Chief Scientific Officer Michael W. Dunne , director & President & CEO Fishman Corey N. , and Chief Medical Officer Sailaja Puttagunta .

Iterum Therapeutics PLC (ITRM) Insider Trades Summary

Over the past 18 months, Canaan X L.p. made no insider transaction in Iterum Therapeutics PLC (ITRM). Other recent insider transactions involving Iterum Therapeutics PLC (ITRM) include a net purchase of 55,000 shares made by Michael W. Dunne , a net purchase of 10,000 shares made by Fishman Corey N. , and a net sale of 3,365 shares made by Sailaja Puttagunta .

In summary, during the past 3 months, insiders sold 0 shares of Iterum Therapeutics PLC (ITRM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 3,365 shares of Iterum Therapeutics PLC (ITRM) were sold and 65,000 shares were bought by its insiders, resulting in a net purchase of 61,635 shares.

Iterum Therapeutics PLC (ITRM)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Iterum Therapeutics PLC Insider Transactions

No Available Data

Canaan X L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Canaan X L.p.. You might contact Canaan X L.p. via mailing address: 2765 Sand Hill Rd, Menlo Park Ca 94025.

Discussions on Canaan X L.p.

No discussions yet.